So-Young International Inc (SY) Q1 2026 Earnings Call Transcript

Why It Matters

The rapid scaling of So‑Young’s aesthetic network validates strong consumer demand and positions the firm to capture higher margins as centers mature, while the expansion‑heavy strategy tests its financial flexibility.

Key Takeaways

• Revenue reaches RMB 451M, 25% YoY increase.
• Aesthetic center revenue jumps 205% to RMB 248M.
• 49 centers operate; 25 achieve profitability.
• Cash drops to RMB 936M for expansion.
• CAC remains under 10% of revenue.

Pulse Analysis

The Chinese medical aesthetic market is entering a phase of consolidation, with consumers favoring trusted, high‑volume providers. So‑Young’s explosive growth in treatment visits—up 178% year‑over‑year—reflects broader shifts toward value‑driven beauty spending and the company’s ability to leverage a nationwide footprint. By scaling to 49 centers and surpassing the 50% revenue contribution threshold, So‑Young demonstrates the economies of scale that can lower per‑procedure costs and improve margin visibility, a critical advantage in a price‑sensitive segment.

Profitability is emerging as a central narrative. Twenty‑five centers achieved break‑even and 39 generated positive operating cash flow, indicating that the mature‑phase locations are delivering nearly double the revenue of growth‑phase sites. This operating leverage, combined with a customer acquisition cost under 10% of revenue, suggests a sustainable unit economics model. However, the decline in cash reserves to RMB 936.4 million and widening non‑GAAP losses highlight the capital intensity of rapid expansion, underscoring the importance of disciplined rollout and cost control.

Looking ahead, So‑Young’s plan to open at least 35 new centers in 2026 signals confidence in the scalability of its model, especially in second‑tier cities where mature centers are already matching first‑tier performance. The firm’s focus on compliance, data security (TIA certification), and a robust physician network further strengthens its competitive moat. Investors will watch whether the company can translate its top‑line momentum into consistent profitability without overextending its balance sheet, a balance that could set a benchmark for the broader aesthetic industry in China.